EMA Authorised: Vyxeos liposomal (previously Vyxeos) (daunorubicin hydrochloride;cytarabine) — Jazz Pharmaceuticals Ireland Limited

View source ↗

Summary

Authorised status for Vyxeos liposomal (daunorubicin hydrochloride; cytarabine) for acute myeloid leukemia in Europe.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• Vyxeos liposomal (daunorubicin hydrochloride; cytarabine (liposomal formulation))

Snippet

Status: Authorised. Therapeutic area: Leukemia, Myeloid, Acute. MAH: Jazz Pharmaceuticals Ireland Limited. Decision date: 29/07/2026. Orphan medicine